


Microangiopathy and microvasculitis: age and vaccine distribution, VAERS data* (U.S. and foreign), 1990.07–2024.08.30†

Draft v32.5



	Janssen COVID-19	Moderna COVID-19	Pfizer/BioNTech COVID-19	Unknown manufacturer COVID-19	All COVID-19 2020.12.14–2024.08.30	All non-COVID-19 1990.07–2020.12.13
<i>n</i> VAERS IDs	41	198	578	10	827	185
μ , Mean‡‡	65.6	65.1	60.3	64.6	61.8	50.6
\hat{x} , Median‡‡	69.0	68.0	63.0	68.0	65.0	55.5
σ , Standard deviation‡‡	16.0	16.8	19.1	15.9	18.4	24.4
γ , Skewness‡‡	-0.7	-0.6	-0.5	-0.8	-0.6	-0.6
<i>n</i> Hospitalized	29	128	386	3	546	81
<i>n</i> Life threatening	5	32	94	0	131	23
<i>n</i> Recovered	10	43	63	0	116	45
<i>n</i> Not recovered	23	109	399	4	535	88
<i>n</i> Died	4	17	24	0	45	11

†Terms queried in SYMPTOM fields 1–5 include: microangiopathy, microvascular (dysfunction/disease), (cerebral/coronary/cutaneous) small vessel disease, microvasculitis, and (IgA/small vessel) vasculitis. ‡n IDs are all COVID-19.

‡‡NLP was used to extract age values from SYMPTOM TEXT and fill in missing data. Remaining reports with unknown age are neither plotted, nor included in calculations, but are included in subtotals. ✉Symbols link to OpenVAERS.

*VAERS disclaimer (excerpts): "... VAERS is designed to rapidly detect unusual or unexpected patterns of adverse events, also known as 'safety signals.' " "The inclusion of events in VAERS data does not infer causality." vaers.hhs.gov